You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
創勝集團-B(06628.HK)在2022年ASCO年會展示TST001及MSB0254臨牀試驗數據最新業務進展
格隆匯 04-29 08:14

格隆匯4月29日丨創勝集團-B(06628.HK)發佈公吿,2022年美國臨牀腫瘤學會年會(“2022年 ASCO年會”)已接受TST001及MSB0254的摘要。摘要名稱分別為:“高親和力人源化抗CLDN18.2單克隆抗體TST001聯合卡培他濱和奧沙利鉑(CAPOX)作為晚期胃癌╱胃食管連接部癌一線治療的I期臨牀研究”,以及“一項評估MSB0254在中國實體瘤患者中的安全性、耐受性和藥代動力學的I期臨牀研究”。

根據披露,ASCO年會展示最前沿的臨牀腫瘤學科研成果和最先進的腫瘤治療技術,是全球腫瘤領域最重要的、最為權威的學術交流盛會。本屆ASCO年會將於2022年6月3 日至7日在伊州芝加哥McCormick會議中心以線上線下形式舉辦。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account